Overview
Spotlight on IRON CLAD: Clinical Review of IV Iron Replacement Therapy for Cancer- and Chemotherapy-Induced Anemia
15-minute vlog
Click the"View Activity" button to view this activity.
View ActivityCME/CE is no longer available for this activity
This quick, comprehensive video reviews the diagnosis and treatment of cancer- and chemotherapy-induced anemia (CIA). Expert faculty, Dr. Jeffrey Gilreath from University of Utah Hospitals and Clinics discusses the role of intravenous (IV) iron replacement monotherapy, including ferric carboxymaltose (FCM), recent clinical trial data supporting its benefit in treatment of CIA, and management of adverse events in patients receiving this therapy.
This activity is intended for hematologists, oncologists, and other clinicians who manage patients with cancer.
The purpose of this activity is to increase knowledge and competence regarding the diagnosis and treatment of chemotherapy-induced anemia, as well as awareness on the therapeutic potential of intravenous iron therapies for treating patients with this condition.
Upon completion of this activity, participants will be able to:
• Discuss the current treatment landscape for cancer-related and chemotherapy-induced anemia (CIA)
• Review the clinical efficacy and safety of IV iron in patients with CIA
• Describe the therapeutic potential of IV iron for the treatment of anemia associated with malignancy
• Discuss the current treatment landscape for cancer-related and chemotherapy-induced anemia (CIA)
• Review the clinical efficacy and safety of IV iron in patients with CIA
• Describe the therapeutic potential of IV iron for the treatment of anemia associated with malignancy
Sponsored by the Academy for Continued Healthcare Learning.
Supported by an educational grant from American Regent.
- Overview of chemotherapy-induced anemia (CIA)
- Diagnosis of CIA
- Current treatment landscape and unmet needs
- Trial design for IRON CLAD
- Safety and efficacy endpoints
- Clinical implications to practice
- Improved response to cancer treatment/overall survival
- Impact on quality of life
- Adverse event management
- Optimal timing for IV iron treatment
- Future directions
Jeffrey Gilreath, PharmD
Clinical Professor of Pharmacy
Department of Pharmacotherapy
Clinical Hematology/Oncology Pharmacist
University of Utah Hospitals and Clinics
Salt Lake City, UT
Clinical Professor of Pharmacy
Department of Pharmacotherapy
Clinical Hematology/Oncology Pharmacist
University of Utah Hospitals and Clinics
Salt Lake City, UT
The Academy for Continued Healthcare Learning (ACHL) requires that the faculty participating in an accredited continuing education activity disclose all affiliations or other financial relationships (1) with the manufacturers of any commercial product(s) and/or provider(s) of commercial services discussed in an educational presentation and (2) with any commercial supporters of the activity. All conflicts of interest have been mitigated prior to this activity.
The following financial relationships have been provided:
Jeffrey Gilreath, PharmD (Faculty)
No financial relationships to disclose.
Discussion of Off-Label, Investigational, or Experimental Drug/Device Use: Iron Dextran, Ferric Gluconate, Iron Sucrose, Ferumoxytol, Ferric Carboxymaltose (FCM), Ferric Derisomaltose
ACHL staff members and others involved with the planning, development, and review of the content for this activity have no relevant affiliations or financial relationships to disclose.
The content for this activity was developed independently of the commercial supporter. All materials are included with permission. The opinions expressed are those of the faculty and are not to be construed as those of the publisher or grantor.
This educational activity was planned and produced in accordance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education. Recommendations involving clinical medicine in a continuing medical education (CME/CE) activity must be based on evidence that is accepted within the profession of medicine as adequate justification for their indications and contraindications in the care of patients. All scientific research referred to, reported, or used in CME/CE in support or justification of a patient care recommendation must conform to the generally accepted standards of experimental design, data collection, and analysis.
This CME/CE activity might describe the off-label, investigational, or experimental use of medications and/or devices that may exceed their FDA-approved labeling. Physicians should consult the current manufacturers’ prescribing information for these products. ACHL requires the speaker to disclose that a product is not labeled for the use under discussion.
This activity will take approximately 15 minutes to complete. To receive credit, participants are required to complete the pretest, view the online activity and complete the posttest and evaluation. To receive credit, 75% must be achieved on the posttest. A certificate will be immediately available. There is no fee to participate in the activity or for the generation of the certificate.
The Academy for Continued Healthcare Learning is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
The Academy for Continued Healthcare Learning designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
